Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

The future of Indian Startup IPOs: Trends and market outlook

By Jagat Joshi
April 11, 2026

After the massive fundraising of 1.95 lakh crores in 2025, many Indian Startup companies are lining up to make their debut in the IPO market. The year 2025 was one of the most active and significant years for the primary market, with the launch of over 365 Initial Public Offerings (IPOs).

Several Startup companies are approaching the IPO route with a genuine focus on the company’s long-term growth vision. So, the question is, how can one trust the Startup IPOs? Through this article, we aim to help you better understand the future of Indian startup IPOs, along with key trends and the overall market outlook.

Strong IPO pipeline indicates market confidence

The IPO momentum shows no sign of slowing down, with 96 companies planning to launch their IPO receiving the SEBI’s approval to raise around ₹1.25 lakh crore. The future of Indian Startup IPOs looks steady, with many startups ready to go public, and several IPOs are lined up. However, investors now believe in investing in financially strong companies that have a clear plan to make profits, rather than startups that chase growth without a sustainable business model.

Focus on profitability over rapid expansion

Earlier, Startup companies only launched their IPOs to grow users quickly, to rapid expansion, setting a higher valuation, with no clear path to sustainable profits. Unlike before, Startup companies are now launching their IPO with a focus on profitability, financial stability, positive cash flow, and consistent revenue growth. This shift gave investors confidence to invest in the start-up companies.

Diverse Sectors

In 2026, we can expect to see the launch of startup IPOs in sectors like fintech, quick commerce, SaaS, renewable energy, Healthcare, logistics, and digital consumer platforms. An innovation-driven business with clear profitability paths is likely to attract investor interest.

SEBI’s regulation

New norms and regulations announced by the SEBI played a vital role in the upcoming startup IPOs in India. An enhanced transparency, stricter disclosure requirements, and introducing a lock-in pledged pre-issue shares boost investor confidence and trust in the startup IPOs.

Investor Confidence Driving IPOs

The Indian IPO market has become strong with a strong participation of retail investors, mutual funds, domestic investors, and foreign investors. For future startup IPOs as well, we can expect to see the strong participation of the investors, supporting strong listing gains and healthy market growth.

Startups Driving Sustainable Growth

The future of Startup IPO looks strong, steady, and confident rather than uncertain. The startup companies with strong fundamental backgrounds, consistent revenue growth, an experienced management team, and realistic valuations are most likely to attract investor interest. However, startups that are chasing quick growth without a solid business foundation may struggle to sustain their business in the long term.

Upcoming Indian Startups IPO in 2026

The following are several high-profit startup companies that are planning to make their debut in the IPO market soon.

PhonePe

A fintech startup in digital payments has filed a confidential DRHP with SEBI to raise around ₹11,000–₹12,000 crore. It is targeting a valuation of around $15 billion.

Flipkart

An e-commerce startup with Walmart as its parent company has recently received approval to shift its headquarters from Singapore to India before going public.

Zepto

A quick-commerce startup that delivers grocery and everyday essential items within 10 minutes is launching its IPO in 2026. Zepto has already filed its draft paper to raise ₹11,000 crore via an IPO through a confidential filing.

OYO

A hospitality startup that offers budget hotel and travel stays is preparing to launch its IPO. The company has been in discussion with its investment bank for its IPO. The IPO might be launched in early or mid-2026.

boAt

A Consumer electronics & D2C startup company has received the approval of SEBI to raise ₹1,500 crore via an IPO. This IPO includes a fresh issue of ₹500 crores and an offer for sale of ₹1,000 crores.

Canva

One of the growing online graphic design platforms, Canva, is expected to launch its IPO in 2026-2027. The date of the IPO or any other related details has not been announced yet. But the company’s leaders and investors have signaled that the issue will be launched soon. Some analysts said that Canva can be the mega tech IPO, due to its constant revenue growth.

Razorpay

Razorpay, one of India’s leading payment solution providers, is preparing to launch its public issue soon. As per the sources, the firm is planning to raise ₹4500 crore via a fresh issue. The firm has also chosen Kotak Mahindra Capital and Axis Capital as its merchant bankers to bid for the IPO.

Kissht

Kissht (OnEMI Technology solutions) is a growing fintech startup company in India. The firm already received the SEBI’s nod on January 8, 2026, to launch its IPO. Kissht is aiming to raise ₹1000 crore via a fresh issue and around 8.88 lakh shares via an OFS.

Conclusion

For investors, the upcoming years will offer great opportunities with diverse industries launching their IPOs. The future Indian Startup IPOs market seems to be stable and fundamentals-driven. As more stable startup companies plan to go public, the focus on transparency, profitability, and sustainability will strengthen investor confidence for long-term growth.

FAQs

1. Which sectors will lead future startup IPOs?

Sectors like fintech, SaaS, quick commerce, renewable energy, electric vehicles, logistics, healthcare tech, and digital consumer platforms are likely to lead future startup IPOs.

2. Are startup IPOs suitable for long-term investors?

Certainly, startup IPOs can be suitable for long-term investors if the company has strong fundamentals, realistic valuations, and consistent revenue growth.

3. What is the overall outlook for Indian startup IPOs?

The overall outlook for Indian startup IPOs seems very stable and selective. The startup with a scalable business model and strong financials is expected to perform well.

4. Which prominent Indian startups are expected to go public soon?

Several startup companies like PhonePe, Flipkart, Zepto, and OYO are expected to go public in 2026 as a Mainboard IPO.

5. How strong is the upcoming startup IPO pipeline?

The upcoming startup IPO pipeline is looking robust, with 96 companies having received SEBI approval to raise about ₹1.25 lakh crore via an IPO.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.